Incyte Signals Increasing Focus In Dermatology With Villaris Buyout

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

With Opzelura approved for vitiligo in July, Incyte acquires Villaris and its preclinical IL-15-targeted antibody to potentially add to its vitiligo portfolio.

Dermatology
Incyte adds to its dermatology portfolio with Villaris acquisition • Source: Shutterstock

Incyte Corporation already has claimed a key position in the vitiligo treatment market with the July approval of a topical formulation of its JAK1/2 inhibitor ruxolitinib, Opzelura, as the first US approval of a drug therapy for segmental vitiligo. On 3 October, the biotech announced a deal that will expand its vitiligo franchise, paying $70m up front to acquire privately held Villaris Therapeutics and its preclinical IL-15 receptor beta antibody auremolimab for vitiligo and other autoimmune and inflammatory diseases.

[Sidebar#SC146738]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.